Analytical Data
-
Gene name
SSX4
- Application
-
Alternative Names
Cancer/testis antigen 5.4
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O60224
-
Expression Region
1-188aa
-
Molecular Weight
48.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SSX4 is a member of the SSX family of cancer/testis (CT) antigens, which are typically expressed in male germ cells and aberrantly in various tumors, making them potential targets for cancer immunotherapy. Research on SSX4 has gained momentum due to its restricted expression pattern, which provides a promising avenue for developing specific therapeutic interventions with minimal off-target effects. The SSX4 protein is encoded by the X chromosome and is known to be associated with several malignancies, including melanoma and other solid tumors. Studies have indicated that SSX4 can elicit immune responses, highlighting its potential as a target for cancer vaccines and adoptive T cell therapy. Additionally, the understanding of SSX4’s role in tumorigenesis and its immunogenic properties could lead to advancements in personalized cancer treatments, enhancing the efficacy of existing therapies. As a result, ongoing research aims to elucidate the exact mechanisms of SSX4's involvement in tumor immune evasion and to explore its potential as both a biomarker and a therapeutic target in oncology. This research is particularly relevant in the context of developing novel strategies to boost anti-tumor immunity and overcome challenges associated with tumor tolerance.
